Pasireotide in tumor diagnosis and treatment by translational medicine / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 345-347, 2013.
Artículo
en Chino
| WPRIM
| ID: wpr-434409
ABSTRACT
The somatostatin analogue pasireotide is a new type of protein which is the first therapeutic agent targeted to the pituitary.Pasireotide can prevent adrenocorticotropic hormone release and inhibit the growth of tumor cells after coupling with somatostatin receptor of the target cell membranes.Pasireotide has a high binding affinity for most of somatostatin receptor (SSTR) subtypes and in particular for SSTR5.Pasireotide can paly an important role in the new round of new targets for individualized diagnosis and treatment of tumors through the studies of translational medicine.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio diagnóstico
Idioma:
Chino
Revista:
Journal of International Oncology
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS